Trial Profile
A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs Reloxaliase (Primary)
- Indications Hyperoxaluria; Primary hyperoxaluria
- Focus Therapeutic Use
- Acronyms Study 206
- Sponsors Allena Pharmaceuticals
- 13 Nov 2019 According to an Allena Pharmaceuticals media release, company plans to meet with regulatory agencies in the first quarter of 2020 to discuss the registrational path for reloxaliase in high-risk EH patients with CKD.
- 13 Nov 2019 According to an Allena Pharmaceuticals media release, data were presented at the American Society of Nephrology Kidney Week 2019.
- 07 Nov 2019 According to an Allena Pharmaceuticals media release, data from the study will be presented at the American Society of Nephrology Kidney Week 2019.